Eurofarma Innovation and Growth Strategy slide image

Eurofarma Innovation and Growth Strategy

7 eurofarma LEADERSHIP POSITION IN THE MAIN THERAPEUTIC CLASSES Positioned to Further Grow Market Share by ATC Level I Dec/21 Market Size (R$ bn) 18.3 7.0 12.6 3.0 7,7 6,1 22,4 11,6 8,5 8,7 21,7 Sales by Therapeutic Class 13 (%) Growth x Market (1) +4.4% +2.8% +5.0% +7.0% +8.6% +6.6% +8.5% +7.2% (1.8%) (6.2%) (12.2%) R$ 129,8 bn Market Position #2 #2 #3 #4 #5 #5 #6 #6 #9 #10 9.3% 12.9% Nervous System Genitourinary System 8.2% XXX Anti-infective System 9.3% Hormonal System 7.4% 6.6% 4% 5% 3% 23% 9% 13% 5.8% 4.2% 4.1% 6% 3.4% 14% 7% 1.9% 4% + MuscleBones System Blood System Digestive System Cardiovascular & Metabolism System Respiratory System Dermatological OthersĀ² 1- Eurofarma compounding annual growth rate from Sep/2017 to 2021 compared to sector compounding annual growth rate; 2- Others (antineoplastic and immunomodulatory agents + hospital solutions + antiparasitic, insecticide and repellent products + miscellaneous); 3- Considering ATC III classes in which the Company is present as a % of the total addressable market. 12%
View entire presentation